Amivantamab vs Real World (RW) Therapies for Advanced Non-small Cell Lung Cancer (aNSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (E20i) in Japan

Masanobu Okahisa,1 Nikhil Ulagow,2 Shingo Matsuzawa,2 Terufumi Kato,3 Harushi Yabuchi3, Nami Furuya2, Ryo Kanemitsu2, Hye Yook Chun2,3, Akiko Nishiyama2, Keita Yokoyama3, Kazumi Ishiguro3, Hirofumi O. Girato4, Karen Kay Mo Lo5, Jianhui Zhao3, Dae Young Kim3,6, Yuchen Yang12, Cindy Thiow Koon Lim14, Nora J. Kleinman15, Koichi Goto1,7

1Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 2Thoracic Oncology Department, Kanagawa Cancer Center, Yokohama, Japan; 3Respiratory Medicine Department, Hokkaido Cancer Center, Sapporo, Japan; 4Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan; 5Medical Affairs, Janssen Asia Pacific, Singapore; 6Research & Development, Janssen China Research & Development, China; 7Real World Evidence, Janssen Asia Pacific, Singapore; 8Department Of Respiratory Medicine, Okayama University Hospital, Okayama, Japan; 9Medical Affairs, Janssen Asia Pacific, Singapore; 10Real World Solutions, IQVIA Solutions Asia Pte Ltd, Singapore; 11Medical Affairs, Janssen Asia Pacific, Singapore; 12Real World Solutions, IQVIA Hong Kong, Kwai Fong, Hong Kong PRC

RESULTS

BACKGROUND

LC-SCRUM-Asia

- This study provides evidence of the efficacy of amivantamab compared to current systemic anti-cancer therapies in RW practice using an external control arm identified from LC-SCRUM-Asia in Japan (Poster 1109P)
- This analysis further explores the clinical benefit of amivantamab compared to docetaxel (DOC), EGFR tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO) in the same setting.

METHODS

Setting, Data Sources & Study Population

- This was a comparative analysis of data from the CHRYSALIS trial and a Japanese cohort in LC-SCRUM-Asia.
- CHRYSALIS is an open-label, multi-center, single arm clinical trial which seeks to evaluate the safety, pharmacokinetics, and preliminary efficacy of amivantamab.
- CHRYSALIS included adult patients with non-small cell lung cancer (NSCLC) who progressed after or on platinum-based chemotherapy.
- LC-SCRUM-Asia is a lung cancer genomic screening platform with more than 16,000 NSCLC patients enrolled since 2013. It provides various first-line treatments for patients and information on cancer biomarkers, patient clinical characteristics, anti-cancer treatment history and longitudinal clinical outcomes.

Statistical Analyses

- First-time use of DOC, TKIs or IO after platinum-based chemotherapy in external control patients were identified from LC-SCRUM-Asia.
- Clinical outcomes were compared between amivantamab-treated patients and DOC-, TKI- or IO-treated, separately.
- Propensity score weighting (average treatment effect on the treated) was used to weight external control patients with the treatments of interest to the distribution of baseline characteristics (age, sex, smoking status and number of prior lines of therapy in CHRYSALIS).
- Overall survival (OS) and progression-free survival (PFS) were described using Kaplan-Meier (KM) curves and compared using weighted Cox proportional hazards models.
- Overall response rate (ORR) was compared using the weighted Cochran Mantel-Haenszel Chi-Square test.

LUNG CANCER

REFERENCES


Presented at the European Society for Medical Oncology (ESMO) Congress 2022; September 12, 2022; Paris, France